Literature DB >> 23490372

Association of suppressor of cytokine signalling 3 polymorphisms with insulin resistance in patients with chronic hepatitis C.

Y-Y Zheng1, L-F Wang, X-H Fan, C-H Wu, N Huo, H-Y Lu, X-Y Xu, L Wei.   

Abstract

Suppressor of cytokine signalling 3 is thought to be associated with insulin resistance in patients with chronic hepatitis C. We evaluated the role of suppressor of cytokine signalling 3 polymorphisms in determining insulin resistance in patients with chronic hepatitis C. Two hundred and ninety untreated hepatitis C virus-infected patients without diabetes and cirrhosis were genotyped for the SNPs rs4969168, rs4969170 and rs12952093 of suppressor of cytokine signalling 3 using the TaqMan Genotyping Assay. We found that the rs4969170 AA genotype and rs4969170 A allele frequency were significantly more common in the insulin-resistant group than the non-insulin-resistant group (89.5% vs 76.1%, OR = 2.693, 95% CI: 1.221-5.939, P = 0.012 and 94.8% vs 88.0%, OR = 2.463, 95% CI: 1.151-5.271, P = 0.017, respectively). Haplotype G-C was likely associated with non-insulin resistance (adjusted P = 0.011). Multiple logistic regression analysis indicates that the independent risk factors for insulin resistance are the SNP rs4969170 AA genotype (OR = 3.005, 95% CI: 1.194-7.560, P = 0.019), HCV genotype 1 (OR = 2.524, 95% CI: 1.099-5.794, P = 0.029) and BMI (OR = 0.514, 95% CI: 0.265-0.999, P = 0.05).
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23490372     DOI: 10.1111/j.1365-2893.2012.01644.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

1.  Genetic correlation of SOCS3 polymorphisms with infantile asthma: an evidence based on a case-control study.

Authors:  Ying Fang; Xiaoxia Ren; Zhanwei Feng
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B.

Authors:  Min-Ran Li; Hong-Li Xi; Qin-Huan Wang; Feng-Qin Hou; Na Huo; Xia-Xia Zhang; Fang Li; Xiao-Yuan Xu
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

Review 3.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

4.  SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B.

Authors:  Nghiem Xuan Hoan; Hoang Van Tong; Dao Phuong Giang; Bui Khac Cuong; Nguyen Linh Toan; Heiner Wedemeyer; C Thomas Bock; Peter G Kremsner; Le Huu Song; Thirumalaisamy P Velavan
Journal:  Oncotarget       Date:  2017-03-07

5.  Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.

Authors:  Xia-Xia Zhang; Min-Ran Li; Ying Cao; Ren-Wen Zhang; Yu Zhang; Fang Li; Hong-Li Xi; Xiao-Yuan Xu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

6.  Methylation of SOCS3 is inversely associated with metabolic syndrome in an epigenome-wide association study of obesity.

Authors:  Omar Ali; Diana Cerjak; Jack W Kent; Roland James; John Blangero; Melanie A Carless; Yi Zhang
Journal:  Epigenetics       Date:  2016-08-26       Impact factor: 4.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.